In Reply We appreciate the thoughtful comments by Efstathiou et al and Molitoris and Simone, which highlight the merits as well as limitations of our 2018 study1 comparing radical cystectomy (RC) with trimodal therapy (TMT) according to survival and costs. Cost of cancer care is expected to soar up to $174 billion by 2020 in the United States, with bladder cancer contributing up to $6 billion of those costs.2 While survival and quality-of-life outcomes are important, these outcomes must be balanced by costs of treatment to provide high-value cancer care.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Williams SB, Kamat AM, Mehta HB. Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer—Reply. JAMA Surg. 2019;154(2):186. doi:10.1001/jamasurg.2018.4372
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: